iTeos TherapeuticsITOS
ITOS
About: ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Employees: 173
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
6.72% less ownership
Funds ownership: 100.16% [Q3] → 93.44% (-6.72%) [Q4]
10% less funds holding
Funds holding: 149 [Q3] → 134 (-15) [Q4]
30% less capital invested
Capital invested by funds: $373M [Q3] → $262M (-$111M) [Q4]
33% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 40
72% less call options, than puts
Call options by funds: $5.88M | Put options by funds: $21.2M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
107%
upside
Avg. target
$26
254%
upside
High target
$46
534%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo 33% 1-year accuracy 3 / 9 met price target | 121%upside $16 | Overweight Maintained | 29 Apr 2025 |
JP Morgan Brian Cheng 29% 1-year accuracy 5 / 17 met price target | 107%upside $15 | Overweight Maintained | 6 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target | 534%upside $46 | Buy Reiterated | 6 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2025 and provided a business update.
Neutral
GlobeNewsWire
1 month ago
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois.
Neutral
GlobeNewsWire
1 month ago
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial - EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25 - Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027
Positive
Seeking Alpha
2 months ago
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability.
Positive
Zacks Investment Research
3 months ago
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Seeking Alpha
4 months ago
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications.
Neutral
GlobeNewsWire
4 months ago
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized to focus resources on other programs
Neutral
GlobeNewsWire
5 months ago
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:
Neutral
GlobeNewsWire
5 months ago
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones
Negative
Investors Business Daily
7 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Charts implemented using Lightweight Charts™